Fabtech Technologies IPO

Leading Turnkey Biopharma Engineering Provider: Fabtech Technologies has established itself as a key turnkey solution provider in the biopharma engineering space, offering comprehensive services from design to execution.

Strong In-house Technology Capabilities: The company has in-house software and engineering expertise, which enhances efficiency and reduces dependency on external resources.

Diversified Order Book: Fabtech serves multiple industries and geographies, ensuring a well-balanced and risk-mitigated order book across clients and verticals.

Efficient Project Execution: With proven expertise in executing projects across challenging environments, the company has developed strong mandate conversion capabilities.

Consistent Financial Growth: The company has shown steady growth with robust financial metrics, including a Return on Equity (ROE) of 30.46% and Return on Capital Employed (ROCE) of 24.46%.

Sector Dependency: A large portion of Fabtech’s business is concentrated in the biopharma and life sciences sector, making it vulnerable to industry-specific fluctuations.

High Working Capital Needs: The business model requires significant working capital, which may affect liquidity and operational flexibility.

Rising Borrowings: The company’s borrowings increased sharply from Rs. 9.88 crore in FY24 to Rs. 54.62 crore in FY25, indicating higher financial leverage.

Earnings Dilution Post-Issue: The EPS is expected to decline from Rs. 14.34 pre-issue to Rs. 10.45 post-issue due to equity dilution, impacting shareholder value.

Regulatory Compliance Risk: As Fabtech operates globally, any non-compliance with international regulatory standards could disrupt business operations and affect growth.